Skip to main content
Home
FULL MENU Close Menu
Home
Home

Andrew D. Bowser

News

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma

Author:
Andrew D. Bowser
Publish date: December 11, 2020

A 74% complete response rate is encouraging in interim analysis of the phase 2 study, but requires further...

  • Read More

News

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL

Author:
Andrew D. Bowser
Publish date: December 10, 2020

Durable responses were seen among patients with follicular lymphoma and diffuse large B-cell lymphoma, an...

  • Read More

News

Duvelisib response rate encouraging in phase 2 PRIMO trial of patients with r/r PTCL

Author:
Andrew D. Bowser
Publish date: December 7, 2020

Toxicities were manageable in the ongoing dose-expansion phase, which is expected to complete enrollment in...

  • Read More

News

Allogeneic transplant leads to durable remissions in T-cell lymphomas

Author:
Andrew D. Bowser
Publish date: December 6, 2020

Retrospective study demonstrates overall survival over 50% at 5 years, though transplant-related mortality and graft-versus-host disease need to...

  • Read More

News

ZUMA-5: Axi-cel yields high response rate in indolent NHL

Author:
Andrew D. Bowser
Publish date: December 6, 2020

The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...

  • Read More

News

COVID-19–related outcomes poor for patients with hematologic disease in ASH registry

Author:
Andrew D. Bowser
Publish date: December 5, 2020

Preliminary data support “emerging consensus” of substantial morbidity and mortality but do not support...

  • Read More

Article

ASCO advises against PARP inhibitor retreatment in ovarian cancer

Author:
Andrew D. Bowser
Publish date: October 28, 2020

ASCO guidelines detail recommendations for PARP inhibitor treatment in ovarian cancer.

  • Read More

News

OSA diagnoses not carried forward to the inpatient setting

Author:
Andrew D. Bowser
Publish date: October 26, 2020

Missed OSA diagnoses could have especially negative implications for patients who don’t continue on positive airway pressure (PAP) therapy during...

  • Read More

News

Switching to riociguat effective for some patients with PAH not at treatment goal

Author:
Andrew D. Bowser
Publish date: October 23, 2020

The clinical benefit of the switching to the sGC inhibitor was consistent across patient subgroups in the phase 4 REPLACE study.

  • Read More

News

Certain statins linked to lower mortality risk in patients admitted for sepsis

Author:
Andrew D. Bowser
Publish date: October 22, 2020

Statin use was associated with lower mortality, compared with no use, with hydrophilic and synthetic statins besting lipophilic and fungal-derived...

  • Read More

News

COVID-19 experience forced residents to quickly improve patient communication skills

Author:
Andrew D. Bowser
Publish date: October 21, 2020

At the peak of the pandemic in New York City, goals of care discussions became easier, though coping with death remains an issue.

  • Read More

News

National lung cancer screening guidelines may miss younger African American individuals at high risk

Author:
Andrew D. Bowser
Publish date: October 19, 2020

Retrospective analysis finds many lung cancer patients would not have counted as eligible for low-dose CT under guidelines that are being...

  • Read More

News

Fauci: Cautious optimism for COVID-19 vaccine by end of 2020

Author:
Andrew D. Bowser
Publish date: October 18, 2020

Top health official is “cautiously optimistic” for vaccine distribution before end of year, pending favorable safety and efficacy data.

  • Read More

News

COVID-19 outcomes no worse in patients on TNF inhibitors or methotrexate

Author:
Andrew D. Bowser
Publish date: September 16, 2020

No increase was seen in hospitalization and death rates, providing additional support for keeping patients on these immunosuppressive treatments...

  • Read More

News

ctDNA clearance tracks with PFS in NSCLC subtype

Author:
Andrew D. Bowser
Publish date: July 13, 2020

The median progression-free survival was significantly longer for patients with circulating tumor DNA clearance.

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »

Privacy Policy

Do Not Sell My Personal Information

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close